Business

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

Financial Post · September 23, 2026 at 9:04 a.m.

One cGMP batch, manufactured in-house under Optimi’s Health Canada Drug Establishment Licence, supplies both the Canadian trial and Australian clinics VANCOUVER, British Columbia, Sept.

23, 2026 (GLOBE NEWSWIRE) — Optimi

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

More from Financial Post

‘Getting lost in the shuffle’: Why some small businesses fear they’re being left to fight the trade war on their own

Endeavour reports tragic loss of life at Ity mine

Globex Mining Enterprises Inc. Announces Normal Course Issuer Bid

Netflix is paying US$200 million for 2027 Women’s World Cup

More in Business

‘Getting lost in the shuffle’: Why some small businesses fear they’re being left to fight the trade war on their own

Endeavour reports tragic loss of life at Ity mine

Globex Mining Enterprises Inc. Announces Normal Course Issuer Bid

Netflix is paying US$200 million for 2027 Women’s World Cup

ZenaTech Unveils Stacklens™, AI-Powered Smart Safety Glasses Built for Field Technicians and Industrial Workers

OpenAI expects US$70 billion in annualized revenue by end of 2026